4.6 Review

Microglia Purinoceptor P2Y6: An Emerging Therapeutic Target in CNS Diseases

Journal

CELLS
Volume 9, Issue 7, Pages -

Publisher

MDPI
DOI: 10.3390/cells9071595

Keywords

microglia; phagocytosis; neuroinflammation; pro-inflammatory cytokines

Categories

Funding

  1. Canadian Institutes in Health Research (CIHR) [331652]
  2. les Fonds de Recherche du Quebec-Sante (FRQS)
  3. Canada Research Chair in Neuroimmunology

Ask authors/readers for more resources

The purinergic receptor P2Y6 is expressed in immune cells, including the microglia that are implicated in neurological disorders. Its ligand, UDP, is a signaling molecule that can serve as an find-me signal when released in significant quantities by damaged/dying cells. The binding of UDP by P2Y6R leads to the activation of different biochemical pathways, depending on the disease context and the pathological environment. Generally, P2Y6R stimulates phagocytosis. However, whether or not phagocytosis coincides with cell activation or the secretion of pro-inflammatory cytokines needs further investigation. The current review aims to discuss the various functions of P2Y6R in some CNS disorders. We present evidence that P2Y6R may have a detrimental or beneficial role in the nervous system, in the context of neurological pathologies, such as ischemic stroke, Alzheimer's disease, Parkinson's disease, radiation-induced brain injury, and neuropathic pain.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available